Business
Notification of Interim Results
Notification of Interim Results.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 0613R Immupharma PLC 19 September 2017 \n\n \nFOR IMMEDIATE RELEASE 19 SEPTEMBER 2017\n \n \n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\n \nNOTIFICATION OF INTERIM RESULTS\nDate: 27 September 2017\nImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, confirms that it will be announcing its Interim results for the six months ended 30 June 2017 on Wednesday 27 September 2017.\n \n \n-Ends-\n \n \n \n\n\n\n\nFor further information please contact:\n \n\n\n\n\nImmuPharma plc (www.immupharma.org)\n\n\n+ 44 (0) 20 7152 4080\n\n\n\n\nTim McCarthy, Chairman\n\n\n \n\n\n\n\nLisa Baderoon, Head of Investor Relations\nTwitter: @immupharma\n \n\n\n+ 44 (0) 7721 413496\n \n \n\n\n\n\n \n\n\n \n\n\n\n\n \nNorthland Capital Partners Limited (Joint Broker)\nPatrick Claridge, David Hignell, Jamie Spotswood, Corporate Finance\nRob Rees, Corporate Broking\n \n \n\n\n \n+44 (0)20 3861 6625\n\n\n\n\n \n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END NORXVLFFDKFLBBQ\n ","length":4500,"tagName":"div"}]